Although mucoactive
proteins, such as
epidermal growth factor (
EGF), could improve clinical outcomes of intestinal ulcerative diseases, their gastrointestinal application is limited because of their proteolytic digestion or concerns about
tumor promotion. In the present study,
ATP-binding cassette (
ABC) transporter-linked secretion of human
EGF from probiotic Escherichia coli (
EGF-
EcN) was created to promote beneficial actions of the
EGF receptor, which is notably attenuated in patients with intestinal ulcerative
injuries. Preventive and postinjury treatment with
EGF-
EcN alleviated intestinal
ulcers and other readouts of disease severity in murine intestinal
ulcer models.
EGF-
EcN administration promoted the restitutive recovery of damaged epithelial layers, particularly via upward expansion of highly proliferating progenitor cells from the lower crypts. Along with the epithelial barrier benefit,
EGF-
EcN improved goblet cell-associated mucosal integrity, which controls the access of
luminal microbiota to the underlying host tissues. Despite concern about the oncogenic action of
EGF,
EGF-
EcN did not aggravate
colitis-associated colon cancer; instead, it alleviated protumorigenic activities and improved barrier integrity in the lesions. All findings indicate that probiotic bacteria-based precision delivery of human
EGF is a promising mucosal intervention against gastrointestinal
ulcers and malignant distress through crypt-derived barrier restoration.